Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $12,305 |
| Gross Profit | $0 | $0 | $0 | -$12,305 |
| % Margin | – | – | – | – |
| R&D Expenses | $93,798 | $42,318 | $32,361 | $12,305 |
| G&A Expenses | $20,219 | $18,820 | $12,876 | $7,279 |
| SG&A Expenses | $20,219 | $18,820 | $12,876 | $7,279 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$12,305 |
| Operating Expenses | $114,017 | $61,138 | $45,237 | $7,279 |
| Operating Income | -$114,017 | -$61,138 | -$45,237 | -$19,584 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $11,688 | $8,767 | $2,381 | -$81,022 |
| Pre-Tax Income | -$102,329 | -$52,371 | -$42,856 | -$100,606 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$102,329 | -$52,371 | -$42,856 | -$100,606 |
| % Margin | – | – | – | – |
| EPS | -1.71 | -1.08 | -1.06 | -2.63 |
| % Growth | -58.3% | -1.9% | 59.7% | – |
| EPS Diluted | -1.71 | -1.08 | -1.06 | -2.63 |
| Weighted Avg Shares Out | 60,013 | 48,491 | 40,602 | 38,267 |
| Weighted Avg Shares Out Dil | 60,013 | 48,609 | 40,602 | 38,267 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,317 | $10,791 | $2,392 | $84 |
| Interest Expense | $4,068 | $581 | $0 | $0 |
| Depreciation & Amortization | $178 | $184 | $169 | $4 |
| EBITDA | -$98,083 | -$51,606 | -$42,687 | -$19,580 |
| % Margin | – | – | – | – |